Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
As the UK continued to see a mixture of national lockdown measures and regional restrictions to mitigate the coronavirus pandemic, as well as preparing for the end of its transition period with the EU and the end-of-year holiday period, price changes were unusually muted in December.
Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.
With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.
Despite Brexit uncertainty and travel restrictions that have just been imposed on the UK, the country’s generics industry is not expected to suffer major disruptions.
Exemestane 25mg tablets saw their average UK trade price drop by a third in November, according to the latest figures from WaveData.
A new reported commissioned by Australia’s Generic and Biosimilar Medicines Association shows a ‘marked increase’ in confidence for biosimilars among a number of different stakeholders.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.